In contrast, NRAS mutation is the oncogenic driver for serous subtype ovarian carcinoma along with somatic mutation of TP53, germline mutations of BRCA1 and BRCA2, and lower frequencies of NF1, PTEN, and RB1 mutations [53,54]. This evidence concerns the gene BRCA2 and ovarian carcinoma.